medigraphic.com
ISSN 1561-302X (Print)

2023, Number 1

<< Back Next >>

Rev cubana med 2023; 62 (1)

Determination of the minimum inhibitory concentration of batches of topical OLEOZON® against Trichophyton rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum

Cordero HME, Fernández AC, San Juan GJ, Perurena LM, Martínez MG, Velar MR, Ilnait ZM, Cima SG, Ledea LO, Fernández GLA, Fernández TI

Language: Spanish
References: 33
Page: 1-12
PDF size: 531.82 Kb.


ABSTRACT

Introduction: Currently fungal infections affect between 20 and 25% of the population.
Objective: To determine the minimum inhibitory concentration of two batches of OLEOZON® stored at temperatures of 5 and 30 0C in glass and high-density polyethylene containers, for 24 months as part of the stability study of topical OLEOZON®.
Methods: Using the agar dilution method, five concentrations of the product were evaluated against the dermatophytes Trichophyton rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum.
Results: It was found that 8.9 mg/mL was the MIC value for the strains evaluated in this shelf life study; and the same value was observed in the accelerated study against the trichophyton strains, while for epidermophyton floccosum it was 17.8 mg/mL with the exception of the glass bottle container of batch 803295 where 8.9 mg/mL was obtained. The statistical analysis, both in the accelerated study and in shelf life, showed that there is a statistically significant difference between the first and the last month of the trial, these are the most appreciable differences in the batches stored in glass jars. Topical OLEOZON® stored in a high-density polyethylene bottle presented better activity values against dermatophytes.
Conclusions: All the values of the minimum inhibitory concentration found, regardless of the type of container, the time or the storage temperature, show that the product maintains its antifungal activity during the months of study. A similarity was apparent between the strains of the genus trichophyton compared to the genus epidermophyton.


REFERENCES

  1. Su H, Packeu A, Ahmed SA, Al-Hatmi AM, Blechert O, Ilkit M, et al. Species distinction in the Trichophyton rubrum complex. Journal of clinical microbiology. 2019; 57: e00352-19. DOI: https://doi.org/10.1128/JCM.00352-19.1

  2. Ramos Bayas OE. Prevalencia de las micosis en los miembros superiores e inferiores de las personas que residen en la parroquia rural de Pinguilí Santo Domingo del Cantón Mocha. In. Universidad Técnica de Ambato-Facultad de Ciencias de la Salud-Carrera de Laboratorio Clínico 2020. [acceso 14/07/2022]. Disponible en https://repositorio.uta.edu.ec/jspui/handle/123456789/30802.2.

  3. González GN, López EF, Bonafe JM. Tratamiento de las tiñas. FMC. Formación Médica Continuada en Atención Primaria. 2013;20:289-96. DOI: https://doi.org/10.1016/S1134-2072(13)70579-6.3.

  4. De Diego AM. Aspectos clínicos, diagnósticos y terapéuticos de las dermatofitosis. Enfermedades infecciosas y microbiología clínica. 2011;29:33-9. DOI: https://doi.org/10.1016/S0213-005X(11)70025-8.4.

  5. Dogra S, Shaw D, Rudramurthy SM. Antifungal drug susceptibility testing of dermatophytes: Laboratory findings to clinical implications. Indian dermatology online journal. 2019;10:225. DOI: https://doi.org/10.4103/idoj.IDOJ_146_19.5.

  6. Yadav P, Singal A, Pandhi D, Das S. Clinico-mycological study of dermatophyte toenail onychomycosis in New Delhi, India. Indian journal of dermatology. 2015;60:153. DOI: https://doi.org/10.4103/0019-5154.152511.6.

  7. Mayorga J, De León-Ramírez RM, Barrios-Marañon Y. Prevalence of dermatophytosis produced by Trichophyton rubrum. Dermatología Revista Mexicana. 2017 [acceso 15/07/2022];61:108-14. Disponible en: https://dermatologiarevistamexicana.org.mx/article/prevalencia-de-dermatofitosis-producidas-por-trichophyton-rubrum/.7.

  8. Panackal AA, Halpern EF, Watson AJ. Cutaneous fungal infections in the United States: analysis of the national ambulatory medical care survey (NAMCS) and national hospital ambulatory medical care survey (NHAMCS), 1995-2004. International journal of dermatology. 2009;48:704-12. DOI: https://doi.org/10.1111/j.1365-4632.2009.04025.x.8.

  9. Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013. [acceso 14/07/2022]. Disponible en: Drugsafety/ucm362415.htm..

  10. Abdel-Rahman SM. Genetic Predictors of Susceptibility to Dermatophytosis. In Dermatophytes and Dermatophytoses. Springer. 2021;181-96. DOI: https://doi.org/10.1007/978-3-030-67421-2_9.10.

  11. Lopes G, Pinto E, Salgueiro L. Natural products: an alternative to conventional therapy for dermatophytosis? Mycopathologia. 2017;182:143-67. DOI: https://doi.org/10.1007/s11046-016-0081-9.11.

  12. Ugazio E, Tullio V, Binello A, Tagliapietra S, Dosio F. Ozonated oils as antimicrobial systems in topical applications. Their characterization, current applications, and advances in improved delivery techniques. Molecules 2020;25:334. DOI: https://doi.org/10.3390/molecules25020334.12.

  13. Serio F, Pizzolante G, Cozzolino G, D'Alba M, Bagordo F, De Giorgi M, Grassi T, Idolo A, Guido M, De Donno A. A New Formulation Based on Ozonated Sunflower Seed Oil: In Vitro Antibacterial and Safety Evaluation. Ozone. Science & Engineering. 2017; 39:139-47. DOI: https://doi.org/10.1080/01919512.2016.1272405.13.

  14. Gálvez BT, Hernández LL, Iglesias MP, Alonso GR, Crespo LÁ, Trujillo PM. Oleozon en el tratamiento de la gingivitis crónica edematosa y fibroedematosa. Ozone Therapy Global Journal. 2021 [acceso 15/07/2022];11:13-27. Disponible en: http://xn--revistaespaoladeozonoterapia-7xc.es/index.php/reo/article/view/221.14.

  15. Curtiellas Piñol V. Los aceites ozonizados en el tratamiento de enfermedades infecciosas. Enfermedades Infecciosas y Microbiología. 2014 [acceso 15/07/2022] ;34:64-8. Disponible en: https://www.medigraphic.com/pdfs/micro/ei-2014/ei142e.pdf.15.

  16. Menéndez S, Molerio J, Díaz W, Lezcano I, León F, Ledea O, et al. Registro Sanitario Sobre la Aplicación del Aceite de Girasol Ozonizado OLEOZON en la Epidermofitosis. No.1498, Ciudad de La Habana, Cuba; 1999. [acceso 14/07/2022]. Disponible en: Disponible en: https://www.cecmed.cu/registro/rcp/medicamentos/oleozonr-topico. 16.

  17. Díaz M, Fernández H, Dennis P, Hernández R, Martínez G. Renovación del Registro sanitario OLEOZON (r) Tópico. No. 1498,536/02.039;04M, Ciudad de La Habana, Cuba. 2004 y 2009..

  18. Gómez MFD. Usos y propiedades de los aceites vegetales ozonizados. La experiencia cubana. Revista CENIC Ciencias Biológicas. 2010.[acceso 14/07/2022];41:1-12 Disponible en: http://www.redalyc.org/articulo.oa?id=181220509050.18.

  19. CECMED. No 23 R. Requerimientos de los estudios de estabilidad para el registro de productos farmacéuticos nuevos y conocidos. MINSAP. Cuba. 2000:5-22. [acceso14/07/2022]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/Reg_23-00.pdf.19.

  20. Delgado Valverde MM. Impacto de la concentración mínima inhibitoria (cmi) y de los puntos de corte clínicos (clsi y eucast) de las combinaciones betalactámicos/inhibidores de betalactamasas en el pronóstico de bacteriemias por enterobacteriaceae. 2017.[acceso 14/07/2022]. Disponible en: https://idus.us.es/bitstream/handle/11441/73670/Tesis doctoral Mercedes Delgado Valverde.pdf.20.

  21. Delgado MÁ. Eficacia terapéutica del aceite de girasol ozonizado frente a la infección por Malassezia pachydermatis en perros y gatos. Ozone Therapy Global Journal. 2015 [acceso 14/07/2022];5:55-74. Disponible en: http://www.xn--revistaespaoladeozonoterapia-7xc.es/index.php/reo/article/view/71.21.

  22. Ouf SA, Moussa TA, Abd-Elmegeed AM, Eltahlawy SR. Anti-fungal potential of ozone against some dermatophytes. Brazilian Journal of Microbiology. 2016;47:697-702. DOI: https://doi.org/10.1016/j.bjm.2016.04.014.22.

  23. Plaza-Trujillo P, López-Cisneros C-L. Evaluación de la susceptibilidad antifúngica in vitro de T. mentagrophytes y T. rubrum. Maskana. 2021;12:65-70. DOI: https://doi.org/10.18537/mskn.12.02.07.23.

  24. Berkow EL, Lockhart SR, Ostrosky-Zeichner L. Antifungal susceptibility testing: current approaches. Clinical Microbiology Reviews. 2020;33:e00069-19. DOI: https://doi.org/10.1128/CMR.00069-19.24.

  25. Poojary S, Miskeen A, Bagadia J, Jaiswal S, Uppuluri P. A study of In vitro antifungal susceptibility patterns of dermatophytic fungi at a tertiary care center in Western India. Indian journal of dermatology. 2019;64:277. DOI: https://doi.org/10.4103/ijd.IJD_456_18.25.

  26. Méndez CC, Sánchez EG, Martín-Mazuelos E. Actualización de los métodos de estudio de sensibilidad in vitro a los antifúngicos. Enfermedades Infecciosas y Microbiología Clínica. 2019;37:32-9. DOI: https://doi.org/10.1016/S0213-005X(19)30180-6.26.

  27. Díaz Jarabrán MC, Díaz González P, Espinoza Rodríguez J, Carrillo Muñoz AJ. Evaluación del perfil de sensibilidad in vitro de aislamientos clínicos de Trichophyton mentagrophytes y Trichophyton rubrum en Santiago, Chile. Revista Iberoamericana de Micología. 2015;32:83-7. DOI: https://doi.org/10.1016/j.riam.2013.12.002.27.

  28. Maurya VK, Kachhwaha D, Bora A, Khatri PK, Rathore L. Determination of antifungal minimum inhibitory concentration and its clinical correlation among treatment failure cases of dermatophytosis. Journal of Family Medicine and Primary Care. 2019;8:2577. DOI: https://doi.org/10.4103/jfmpc.jfmpc_483_19.28.

  29. Salehi Z, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. European Journal of Clinical Microbiology & Infectious Diseases. 2018;37:1841-6. DOI: https://doi.org/10.1007/s10096-018-3317-4.29.

  30. Geweely NS. Antifungal activity of ozonized olive oil (Oleozone). Int J Agri Biol 2006;8:671-8..

  31. Mattei AS, Beber MA, Madrid IM. Dermatophytosis in small animals. SOJ Microbiol Infect Dis. 2014;2:1-6. DOI: http://dx.doi.org/10.15226/sojmid/2/3/00124.31.

  32. Martínez Sánchez G, Re L, Perez-Davison G, Horat Delaporte R. Las aplicaciones médicas de los aceites ozonizados, actualización. Ozone Therapy Global Journal. 2012. [acceso 17/07/2022];2:121-39. Disponible en: http://xn--revistaespaoladeozonoterapia-7xc.es/index.php/reo/article/view/18.32.

  33. Schwartz A, Martinez-Sanchez G, Re L. Guía para el uso médico del ozono. Fundamentos terapéuticos e indicaciones. 2011 [acceso 17/07/2022]. AEPROMO. Disponible en: https://aepromo.org/guia-para-el-uso-medico-del-ozono-version-online.33.




2020     |     www.medigraphic.com